Immunology and immunopathogenesis of human leishmaniasis

• Autor(a) principal: Juliana P. B. de Menezes
• Data de Publicação: 2022
• Outros Autores: Cláudia Brodskyn, Ricardo Gonçalves, Olivia Bacellar
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: https://doi.org/10.3389/fcimb.2022.1055221; http://hdl.handle.net/1843/61292; https://orcid.org/0000-0002-1127-4483
• topic: Human leishmaniasis; Immunopathogenesis; IL-32; IL-17; Peroxisome proliferator-activated receptor-g (PPAR-g),; Pioglitazone; Leishmania; Pioglitazona; Patogênese Homeopática

Leishmaniasis is a disease that affects people and animals worldwide and can be broadly divided into visceral (VL) and tegumentary (TL) forms. TL caused by Leishmania braziliensis presents a wide spectrum de clinical manifestations ranging from a single and typical ulcer known as CL to the involvement of nasal or oral mucosal, mucosal leishmaniasis (ML). Between both clinical forms, there is diffuse cutaneous leishmaniasis (DCL) caused by Leishmania amazonensis. This spectrum included atypical cutaneous leishmaniasis (ACL) characterized by vegetative, verrucous, crusted and lupoid lesions (Guimarães et al., 2016). Human VL is characterized by depressed cell-mediated immunity and decreased Th1 immune response (Carvalho et al., 1989; Bacellar et al., 2000). Also, VL is associated with increased production of multiple pro-inflammatory cytokines and chemokines (Saporito et al., 2013; Palacios et al., 2021; Tasew et al., 2021).